[1]
|
Khemlina, G., Ikeda, S. and Kurzrock, R. (2017) The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies. Molecular Cancer, 16, 149. https://doi.org/10.1186/s12943-017-0712-x
|
[2]
|
Arrese, M., Hernandez, A., Astete, L., Estrada, L., Cabello-Verrugio, C. and Cabrera, D. (2018) TGF-β and Hepatocellular Carcinoma: When a Friend Becomes an Enemy. Current Protein & Peptide Science, 19, 1172-1179.
https://doi.org/10.2174/1389203718666171117112619
|
[3]
|
夏锋, 李雪松. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(3): 514-518.
|
[4]
|
Boland, P. and Wu, J. (2018) Systemic Therapy for Hepatocellular Carcinoma: Beyond Sorafenib. Chinese Clinical Oncology, 7, 50. https://doi.org/10.21037/cco.2018.10.10
|
[5]
|
Li, Z., Gao, J., Zheng, S.M., et al. (2020) The Efficacy of Sorafenib in Preventing Hepatocellular Carcinoma Recurrence after Resection: A Systematic Review and Meta-Analysis. Revista Espanola de Enfermedades Digestivas, 112, 201-210. https://doi.org/10.17235/reed.2020.6458/2019
|
[6]
|
Abdelgalil, A.A., Alkahtani, H.M. and Al-Jenoobi, F.I. (2019) Sorafenib. Purchase Profiles of Drug Substances, Excipients, and Related Methodology, 44, 239-266. https://doi.org/10.1016/bs.podrm.2018.11.003
|
[7]
|
Liu, G., Kuang, S., Cao, R., Wang, J., Peng, Q. and Sun, C. (2019) Sorafenib Kills Liver Cancer Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids via the ATP-AMPK-mTOR-SREBP1 Signaling Pathway. The FASEB Journal, 33, 10089-10103. https://doi.org/10.1096/fj.201802619RR
|
[8]
|
Li, X.G., Chen, W.R., Liu, K.H., et al. (2020) Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway. SJPD117913229757, 2020 (Default), 8081-8091.
https://doi.org/10.2147/CMAR.S257482
|
[9]
|
Labeur, T.A., Hofsink, Q., Takkenberg, R.B., et al. (2020) The Value of Sorafenib Trough Levels in Patients with Advanced Hepatocellular Carcinoma—A Sub-Study of the SORAMIC Trial. Acta Oncologica, 59, 1028-1035.
https://doi.org/10.1080/0284186X.2020.1759826
|
[10]
|
胡倍源, 覃伟, 董琼珠, 钦伦秀. 肝细胞癌(HCC)对索拉非尼耐药相关机制的研究进展[J]. 复旦学报(医学版), 2018, 45(6): 884-888.
|
[11]
|
Tang, X., Yang, W., Shu, Z., et al. (2019) MicroRNA-223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7. Oncology Reports, 41, 1231-1237. https://doi.org/10.3892/or.2018.6908
|
[12]
|
刘国锟, 郭艳霞. 索拉菲尼治疗晚期肝癌患者的临床疗效和安全性分析[J]. 中国处方药, 2020, 18(7): 77-78.
|
[13]
|
Ai, L., Xu, Z., Yang, B., He, Q. and Luo, P. (2019) Sorafenib-Associated Hand-Foot Skin Reaction: Practical Advice on Diagnosis, Mechanism, Prevention, and Management. Expert Review of Clinical Pharmacology, 12, 1121-1127.
https://doi.org/10.1080/17512433.2019.1689122
|
[14]
|
Wang, P., Tan, G., Zhu, M., Li, W., Zhai, B. and Sun, X. (2018) Hand-Foot Skin Reaction Is a Beneficial Indicator of Sorafenib Therapy for Patients with Hepatocellular Carcinoma: A Systemic Review and Meta-Analysis. Expert Review of Gastroenterology & Hepatology, 12, 1-8. https://doi.org/10.1080/17474124.2017.1373018
|
[15]
|
Jiang, Y., Chen, M., Nie, H. and Yuan, Y. (2019) PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics, 15, 1111-1122.
https://doi.org/10.1080/21645515.2019.1571892
|
[16]
|
Voutsadakis, I.A. (2019) PD-1 Inhibitors Monotherapy in Hepatocellular Carcinoma: Meta-Analysis and Systematic Review. Hepatobiliary & Pancreatic Diseases International, 18, 505-510. https://doi.org/10.1016/j.hbpd.2019.09.007
|
[17]
|
Ghavimi, S., Apfel, T., Azimi, H., Persaud, A. and Pyrsopoulos, N.T. (2020) Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. Journal of Clinical and Translational Hepatology, 8, 168-176. https://doi.org/10.14218/JCTH.2020.00001
|
[18]
|
Finkelmeier, F., Waidmann, O. and Trojan, J. (2018) Nivolumab for the Treatment of Hepatocellular Carcinoma. Expert Review of Anticancer Therapy, 18, 1169-1175. https://doi.org/10.1080/14737140.2018.1535315
|
[19]
|
Feng, D., et al. (2017) Initial Experience of Anti-PD1 Therapy with Nivolumab in Advanced Hepatocellular Carcinoma. Oncotarget, 8, 96649-96655. https://doi.org/10.18632/oncotarget.20029
|
[20]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|